我们对接受唑来膦酸（ZOA）初始治疗的多发性骨髓瘤（MM）患者的外周血（PB）中γδT细胞和尿液中I型胶原N端肽（uNTX）的动态变化进行了前瞻性评估；Zobonic®，TTY，台湾）。 2012年3月至2015年11月期间，共有35名患者入组，其中25名新诊断的MM（NDMM）患者。在第一次 ZOA 输注前 20 天，然后在输注后第 8 天、第 64 天和第 85 天评估 PB 中 γδT 细胞的百分比。同时，还测量了 uNTX 水平。随后的分析中纳入了 33 名接受过至少一剂 ZOA 的患者。我们确定了γδT细胞的三种动态变化模式：波动模式、持续增加模式和持续减少模式。在 NDMM 患者中，与其他两种模式的患者相比，表现出持续增加模式的患者的总生存期显着缩短（4.7 个月 vs. 92.9 个月，p = 0.037）。对于 uNTX，其水平在 ZOA 治疗后显着下降。总之，我们的研究结果揭示了 ZOA 启动后 γδT 细胞的三种不同的动态变化模式，持续增加的模式与不良预后相关。这些发现促使人们进一步探究 γδT 细胞在 MM 患者中的作用，并支持 γδT 细胞及其相关肿瘤微环境的抑制性质。版权所有 © 2024 台湾医学会。由 Elsevier B.V. 出版。保留所有权利。

We conducted a prospective evaluation for the dynamic change of γδT cells in peripheral blood (PB) and N-telopeptide of type I collagen in urine (uNTX) of patients diagnosed with multiple myeloma (MM) who underwent their initial treatment with zoledronic acid (ZOA; Zobonic®, TTY, Taiwan). Between March 2012 and November 2015, a total of 35 patients were enrolled, including 25 newly diagnosed MM (NDMM) patients. The percentage of γδT cells in PB was assessed at 20 days prior to the first ZOA infusion, then at day 8, day 64, and day 85 after the infusion. Simultaneously, uNTX levels were measured as well. Thirty-three patients who had received at least one dose of ZOA were included in subsequent analysis. We identified three dynamic change patterns for γδT cells: fluctuated pattern, continuously increasing pattern, and continuously decreasing pattern. Among NDMM patients, those exhibiting a continuously increasing pattern showed a significantly shorter overall survival compared to those with the other two patterns combined (4.7 months vs. 92.9 months, p = 0.037). For uNTX, which levels significantly decreased following ZOA treatment. In conclusion, our findings reveal three distinct dynamic change patterns for γδT cells after ZOA initiation, with continuously increasing pattern being associated with a poor prognosis. These findings prompt further inquiry into the role of γδT cells in MM patients and support the suppressive nature of γδT cells and their associated tumor microenvironment.Copyright © 2024 Formosan Medical Association. Published by Elsevier B.V. All rights reserved.